Emerging therapies for small cell lung cancer

Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembrolizumab, atezolizumab, and durvalumab have led to significant improvements in clinical outcome...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of hematology and oncology Ročník 12; číslo 1; s. 47 - 11
Hlavní autoři:	Yang, Sen, Zhang, Zhe, Wang, Qiming
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London BioMed Central 02.05.2019 BioMed Central Ltd Springer Nature B.V BMC
Témata:	Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Research Cancer therapies Cancer treatment Carboplatin Care and treatment Chemotherapy Clinical trials Cytotoxicity Drug dosages Hematology Humans Immunotherapy Immunotherapy - methods Ipilimumab Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - pathology Medical prognosis Medicine Medicine & Public Health Metastasis Methods Monoclonal antibodies Neutropenia Oncology Orphan drugs Pembrolizumab Review RNA polymerase Small cell lung cancer Small cell lung carcinoma Small Cell Lung Carcinoma - drug therapy Small Cell Lung Carcinoma - pathology Targeted cancer therapy Targeted therapy China Small cell lung cancer Chemotherapy Targeted therapy Immunotherapy
ISSN:	1756-8722, 1756-8722
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!